scholarly journals Study on the Clinical Efficacy and Safety of Endostar Combined with Pemetrexed and Cisplatin in the Treatment of Lung Adenocarcinoma

2020 ◽  
Vol 4 (6) ◽  
Author(s):  
Yanbing Wang
Keyword(s):  
Lung Adenocarcinoma ◽  
Clinical Efficacy ◽  
Adverse Reactions ◽  
Treatment Plan ◽  
Specific Treatment ◽  
Control Group ◽  
Efficacy And Safety ◽  
Treatment Results ◽  
Significant Difference ◽  
Experimental Group

Objectives: To analyze and study the efficacy and safety of Endu combined with pemetrexed and cisplatin in the clinical treatment of lung adenocarcinoma. Methods: From August 2016 to September 2020, 32 patients with lung adenocarcinoma who were treated in our hospital were selected for group trials. According to their specific treatment plan, the patients were divided into control group and experimental group, with 16 cases in each group. The control group was treated with pemetrexed and cisplatin, and the experimental group was treated with Endostar combined with the treatment received by the control group. The clinical efficacy and safety of the two regimens were assessed by comparing the changes in symptoms and the incidence of adverse reactions between the two groups of patients after treatment. Results: The disease control rate of the experimental group was significantly higher than that of the control group, and there was no significant difference in the incidence of adverse reactions between the two groups. Conclusions: From the experimental results, we found that the treatment of patients with lung adenocarcinoma by Endostar combined with pemetrexed and cisplatin can effectively improve the treatment efficacy without increasing adverse reactions and therefore relevant chemotherapy regimens can be considered for wider clinical applications.

scholarly journals Meta-Analysis of Clinical Efficacy and Safety of Ligustrazine in the Treatment of Idiopathic Pulmonary Fibrosis

2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Xiaozheng Wu ◽  
Wen Li ◽  
Zhenliang Luo ◽  
Yunzhi Chen
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Clinical Efficacy ◽  
Adverse Reactions ◽  
Clinical Symptoms ◽  
Gas Analysis ◽  
Control Group ◽  
Efficacy And Safety ◽  
Arterial Blood Gas ◽  
Arterial Blood

Objective. To systematically review the efficacy and safety of Ligustrazine in the treatment of idiopathic pulmonary fibrosis (IPF). Methods. The electronic literature databases (PubMed, EMbase, CNKI, WanFang database, and VIP) were retrieved through a computer to find out the randomized controlled trials (RCT) of Ligustrazine in the treatment of IPF according to the inclusion/exclusion criteria screening test. Cochrane’s bias risk table was also used to evaluate the quality of the study and to extract effective data. RevMan 5.3 was used for statistical analysis. Results. A total of 7 RCTs (a total of 366 patients, including 196 in experimental and 170 in control group). Compared with the control group, Ligustrazine could improve the clinical symptoms ([OR] = 2.20, 95% CI [1.40, 3.46], P = 0.0006 ), lung function (VC % [MD] = 3.92, 95% CI [0.68, 7.17], P = 0.02 ), (TLC% [MD] = 4.94, 95% CI [0.37, 9.52], P = 0.03 ), the pulmonary diffusion function (DLCO % [MD] = 9.12, 95% CI [5.70, 12.55], P < 0.00001 ), and arterial blood gas analysis (PaO2 [MD] = 7.11, 95% CI [1.96, 12.25], P = 0.007 ) (PaCO2 [MD] = −2.42, 95% CI [−4.36, −0.49], P = 0.01 ) of IPF patients, respectively. However, FEV1/FVC % ([MD] = 9.37, 95% CI [−1.23, 19.97], P = 0.08 ) and adverse reactions ([MD] = 0.35, 95% CI [0.02, 5.36], P = 0.45 ) were not significantly improved. Conclusion. Ligustrazine has certain clinical efficacy in the treatment of IPF, but the safety of applying it and the adverse reactions need to be further analyzed and determined. It can be considered as a new alternative and complementary medicine to be promoted and recommended for use in medical units in various countries in the world and it solved the difficult problem of conventional drug treatment of IPF; therefore, more research strength can be put in the treatment of the pathological mechanism of IPF for further exploration. The study was registered under registration number CRD42020193626.

scholarly journals Therapeutic effect of nifedipine combined with enalapril on elderly patients with coronary heart disease complicated with hypertension

2018 ◽  
Vol 2 (6) ◽  
Author(s):  
Xiaoye Wang
Keyword(s):  
Blood Pressure ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Elderly Patients ◽  
Adverse Reactions ◽  
Effective Rate ◽  
Control Group ◽  
Significant Difference ◽  
Pre Treatment ◽  
Experimental Group

【Abstract】Objective: Toanalyze the efficacy of combined drug therapy for elderly patients with coronary heart disease and hypertension.METHODS:Sixty-six elderly patients with coronary heart disease and hypertension were enrolled from December 2017 to November 2018. They were randomly divided into two groups, 33 patients in each group. Patients in the experimental group received nifedipine. In combination with enalapril, patients enrolled in the control group received nifedipine monotherapy.RESULTS:Compared with the control group, the total effective rate, Serum Nitric Oxide (Serum NO) after treatment, CRP after treatment, HCY after treatment, and blood pressure after treatment were significantly improved (P<0.05). Serum NO and treatment before treatment in the 2 groups. There was no significant difference in pre-CRP, pre-treatment HCY, pre-treatment blood pressure, and adverse reactions during treatment (P>0.05).Conclusion: Theelderly patients with coronary heart disease and hypertension are treated with nifedipine and enalapril.

scholarly journals Efficacy and safety of percutaneous transforaminal endoscopic discectomy in the treatment of lumbar spinal stenosis combined with osteoporosis

2019 ◽  
Vol 65 (6) ◽  
pp. 779-785
Author(s):  
Xiaobin Gu ◽  
Wenhui Zhu ◽  
Haiyi He ◽  
Zili Wang ◽  
Shaolong Ding ◽  
...  
Keyword(s):  
Spinal Stenosis ◽  
Lumbar Spinal Stenosis ◽  
Adverse Reactions ◽  
Leg Pain ◽  
Control Group ◽  
Efficacy And Safety ◽  
Significant Difference ◽  
Endoscopic Discectomy ◽  
Percutaneous Transforaminal Endoscopic Discectomy ◽  
Lumbar Spinal

SUMMARY OBJECTIVE: To investigate the efficacy and safety of percutaneous transforaminal endoscopic discectomy (PTED) in the treatment of lumbar spinal stenosis (LSS) combined with osteoporosis. METHODS: Eighty patients with LSS combined with osteoporosis were divided into a control and PTED group, which received conventional transforaminal lumbar interbody fusion and PTED, respectively. The surgical indications, incision visual analogue scale (VAS), lumbar and leg pain VAS, lumbar Japanese Orthopaedic Association (JOA) and Oswestry disability index (ODI) scores, bone mineral density (BMD), and adverse reactions were observed. RESULTS: Compared with the control group, in the PTED group, the operation time, bleeding loss and hospitalization duration, incision VAS scores at postoperative 12, 24 and 48 h and lumbar and leg pain VAS and lumbar ODI scores on postoperative 6 months were significantly decreased (P < 0.01), and the lumbar JOA score on postoperative 6 months was significantly increased (P < 0.05). There was no significant difference in BMD between two groups (P > 0.05). Compared with the control group, in the PTED group, the total effective rate was significantly higher (P < 0.05), and the incidence of adverse reactions was significantly lower (P < 0.05). CONCLUSIONS: PTED is safe and effective in the treatment of LSS combined with osteoporosis.

scholarly journals Clinical efficacy of plasma exchange therapy for treatment of autoimmune bullous skin disease

2019 ◽  
Vol 3 (4) ◽  
Author(s):  
Xiaoxu Shi ◽  
Lanying Qin ◽  
Jun Peng ◽  
Zishen Zhao ◽  
Haixiang Zhang
Keyword(s):  
Plasma Exchange ◽  
Clinical Efficacy ◽  
Skin Disease ◽  
Treatment Method ◽  
Control Group ◽  
Short Term ◽  
Plasma Exchange Therapy ◽  
Significant Difference ◽  
The Difference ◽  
Experimental Group

Objective: To investigate the clinical efficacy of plasma exchange therapy for autoimmune bullous skin disease. METHODS: Fifty patients with autoimmune bullous skin disease enrolled in our hospital from January 2018 to January 2019 were selected. The patients were grouped by treatment method: 25 control group patients were given conventional hormone therapy, while 25 experimental group patients were treated with plasma exchange therapy; efficacy of treatment was compared between two groups of patients. RESULTS: Initial dose, maximum dose, and cumulative dose of glucocorticoids were lower in experimental group patients than those in control group (P<0.05). Incidence of complication was lower in experimental group patients than those in control group (P<0.05); the difference was significant. There was no significant difference in short-term efficacy between the two groups (P>0.05). Conclusion: The application of plasma exchange therapy was effective for treatment of autoimmune bullous skin disease. It could reduce dosage amount of glucocorticoids and incidence of complications; its application can be promoted.

scholarly journals Efficacy and Safety of Mecobalamin Combined with Prokinetic Agents in the Treatment of Diabetic Gastroparesis: A Meta-Analysis

2021 ◽  
Author(s):  
Jia Yao ◽  
Bo Peng ◽  
Xiayu Gong ◽  
Xiaoyan Shi ◽  
Simin Fan ◽  
...  
Keyword(s):  
Recurrence Rate ◽  
Adverse Reactions ◽  
Meta Analysis ◽  
Diabetic Gastroparesis ◽  
Control Group ◽  
Efficacy Rate ◽  
Efficacy And Safety ◽  
Prokinetic Drugs ◽  
Prokinetic Agents ◽  
Experimental Group

Background: The aim of the present study was to systematically review the efficacy and safety of mecobalamin combined with prokinetic agents in diabetic gastroparesis (DGP). Methods: A variety of databases were searched from inception to Nov 2, 2018. RCTs of mecobalamin combined with prokinetic agents group (experimental group) versus prokinetic agents only group (control group) in DGP were included. RevMan 5.3 and Stata 12.0 were used to perform the meta-analysis. Finally, 24 RCTs with 1,878 patients were included. Results: The total efficacy rate was significantly higher in the experimental group (mecobalamin combined with prokinetic drugs) compared with the control group (prokinetic drugs alone) (P<0.001), and the improvement was observed regardless of the administration route. Furthermore, the treatment group exhibited a significantly improved gastric emption rate (P<0.001), motilin (P<0.001) and recurrence rate (P<0.001), and there was no statistical difference in the incidence of adverse reactions between two groups (P=0.49). Conclusion: Mecobalamin combined with prokinetic agents can significantly improve total efficacy rate and gastric emptying rate, decrease serum motilin and the recurrence rate without increasing adverse reactions in DGP. Thus, mecobalamin may can be used as a new therapeutic option for DGP.

Effect of Levosimendan on the short-term clinical efficacy of patients with acute decompensated heart failure

2021 ◽  
Vol 7 (6) ◽  
pp. 6572-6584
Author(s):  
Wang Huping ◽  
Wang Shidong ◽  
Rong A ◽  
Xie Xueliang
Keyword(s):  
Heart Failure ◽  
Heart Disease ◽  
Clinical Efficacy ◽  
Adverse Reactions ◽  
Heart Function ◽  
Acute Decompensated Heart Failure ◽  
Decompensated Heart Failure ◽  
Control Group ◽  
Clinical Effects ◽  
Significant Difference

OBJECTIVE To observe the effect of levosimendan on the clinical efficacy of patients with acute decompensated heart failure (ADHF). METHODS Collected 124 patients with acute decompensated heart failure who were admitted to the cardiology department of our hospital from October 2019 to October 2020. According to the random number table method, they were divided into control group and levosimendan group. The control group was given traditional anti-heart failure treatment, and the levosimendan group was added with levosimendan injection on the basis of the control group. The clinical efficacy indicators, functional indicators, incidence of adverse reactions, mortality during hospitalization, rehospitalization rates and combined endpoint events within 3 months of follow-up were compared before and after treatment. RESULT The results of clinical efficacy comparison showed that the number of significant effective number in the controlgroup was less than that of the levosimendan group, and there was no difference in the number of effective, ineffective and total effective groups; the improvement of dyspnea after treatment in the levosimendan group was better than that of the control group; cardiac color Doppler ultrasound LVEF in control group is higher than Levosimendan group, LVEDV and LVESV are lower than control group; The BNP control group was higher than the levosimendan group. There was no significant difference in renal function between the two groups.The urine output of the control group was less than that of the levosimendan group.There was no statistically significant difference in adverse reactions, rehospitalization rates within 3 months, and mortality between the two groups of patients, and the combined endpoint event (death or rehospitalization) was significantly lower than that of the control group. CONCLUSION Levosimendan in the treatment of patients with acute decompensated heart failure can achieve significant clinical effects, and effectively improve the patient's hemodynamic indicators and increase renal perfusion.With the deepening of the aging of the population in China, the incidence of decompensated heart failure in the elderly population is higher, which seriously affects the normal life. Acute decompensated heart failure (ADHF), a kind of heart disease, is a clinical syndrome characterized by dyspnea with sudden onset and rapid peak based on abnormal heart function (11. It is typical of the late stage of heart disease, usually on the basis of chronic heart failure. The disease is complex and difficult to treat. In addition, the mortality rate of patients is high [2], which endangers the health of patients and threatens their life safety, and is the key disease of current clinical attention. At present, drug therapy is mainly adopted in the clinical treatment to stabilize the hemodynamic level of patients. Clinical practice shows that it is not significantthe to adopt conventional symptomatic treatment effect/which demands a new effective treatment scheme. Levosimendan .a new type of positive inotropic drug, -can increase myocardial contractility and has significant effects in improving heart failure which will reduce mortality, improve the incidence of arrhythmia and bring hope to patients [3]. This study took 124 cases admitted to our hospital as the research object, and analyzed the therapeutic effect of levosimendan. The report are as follows.

scholarly journals Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance —A Multicenter Randomized Trial

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Ping Fang ◽  
Liqin Zhang ◽  
Xianru Zhang ◽  
Jiawen Yu ◽  
Jun Sun ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Kinase Inhibitors ◽  
Controlled Trial ◽  
Objective Response ◽  
Control Group ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Significant Difference ◽  
Tki Resistance ◽  
Egfr Tki

Abstract Few pieces of evidence have been published on the use of Apatinib Mesylate (AM) against EGFR-TKI resistance in lung adenocarcinoma (LA) patients. Here, we investigate the clinical efficacy and safety of AM in the treatment of advanced progressed epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) resistant LA patients. We conducted a double-blind, randomized controlled trial in 68 patients admitted to 18 hospitals of Anhui province in China. The efficacy and safety of AM treatment were evaluated in terms of progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR), as well as related adverse events (AE). A literature knowledge database analysis and a pathway model reconstruction were performed to decipher the relevant mechanism may be involved. Our results showed that, compared to the control group, AM presented improved efficacy in PFS (P = 0.033), ORR (P < 0.001), and DCR (P < 0.001). No significant difference was observed between case and control group in terms of AE, and no drug-related death occurred. Pathway analysis supports that Apatinib can be repurposed for the treatment of LA. Our results suggested that AM could be a potential option for advanced progressed LA patients to combat EGFR-TKI resistance.

scholarly journals The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Yue Zhou ◽  
Mei He ◽  
Rui Li ◽  
Yuan Peng ◽  
Feng Li ◽  
...  
Keyword(s):  
Adverse Reactions ◽  
Meta Analysis ◽  
Small Cell ◽  
Control Group ◽  
Controlled Trials ◽  
Small Cell Lung ◽  
Randomized Controlled ◽  
Significant Difference ◽  
Hemorrhagic Events ◽  
Experimental Group

Objective. Bevacizumab was currently available for nonsquamous non-small-cell lung cancer (NSqNSCLC) patients and has been studied in several randomized controlled trials (RCTs) for treatment of these patients. This meta-analysis summarizes the most up-to-date evidences regarding the effects and adverse reactions of bevacizumab in the treatment of NSqNSCLC patients. Methods. The authors searched for RCTs from electronic database including PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. Experimental arm was defined as the bevacizumab-containing group and the control arm as the bevacizumab-free group. Data of objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse reactions were synthetically extracted. A protocol for this meta-analysis has been registered on PROSPERO (http://www.crd.york.ac.uk/prospero). Results. Ten RCTs that involved a total of 3134 patients were included. The experimental group was associated with significant superior ORR (RR 1.63, 95% CI 1.24 to 2.14, P < 0.001 ), OS (HR 0.90, 95% CI 0.82 to 0.99, P < 0.001 ), and prolonged PFS (HR 0.68, 95% CI 0.62 to 0.74, P < 0.001 ) compared to the control. No significant difference was observed regarding DCR (RR 1.13, 95% CI 0.99 to 1.30, P = 0.08 ). The experimental group showed higher rate of hypertension (RR 6.91, 95% CI 4.62 to 10.35, P < 0.00001 ) and hemorrhagic events (RR 3.07, 95% CI 1.78 to 5.30, P < 0.0001 ) than the control group. The experimental group showed lower rate of anemia (RR 0.72, 95% CI 0.55 to 0.96, P = 0.02 ) than the control group. No significant difference was observed regarding treatment-related adverse event grade 3-5 (TRAE3-5) (RR 1.23, 95% CI 0.99 to 1.53, P = 0.06 ), thrombocytopenia (RR 1.11, 95% CI 0.92 to 1.33, P = 0.29 ), and neutropenia (RR 1.11, 95% CI 0.88 to 1.40, P = 0.36 ). Conclusion. This meta-analysis showed that bevacizumab could increase ORR, OS, and prolonged PFS for treatment of NSqNSCLC patients. However, no significant improvement in DCR was observed and bevacizumab could increase the rate of hypertension and hemorrhagic events. Bevacizumab was an acceptable option for NSqNSCLC patients. This trial is registered with PROSPERO registration number: CRD42021226790.

scholarly journals Efficacy and Safety of Acupuncture for Acute Low Back Pain in Emergency Department: A Pilot Cohort Study

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Yen-Ting Liu ◽  
Chih-Wen Chiu ◽  
Chin-Fu Chang ◽  
Tsung-Chieh Lee ◽  
Chia-Yun Chen ◽  
...  
Keyword(s):  
Emergency Department ◽  
Cohort Study ◽  
Low Back Pain ◽  
Back Pain ◽  
Control Group ◽  
Low Back ◽  
Efficacy And Safety ◽  
Acute Low Back Pain ◽  
Significant Difference ◽  
Experimental Group

Introduction. Low back pain (LBP) is one of the most common complaints in the emergency department (ED). There are several research articles providing evidence for acupuncture for treating chronic LBP but few about treating acute LBP. This study assessed the efficacy and safety of acupuncture for the treatment of acute LBP in the ED.Materials and methods. A clinical pilot cohort study was conducted. 60 participants, recruited in the ED, were divided into experimental and control groups with 1 dropout during the study. Life-threatening conditions or severe neurological defects were excluded. The experimental group (n=45) received a series of fixed points of acupuncture. The control group (n=14) received sham acupuncture by pasting seed-patches near acupoints. Back pain was measured using the visual analog scale (VAS) at three time points: baseline and immediately after and 3 days after intervention as the primary outcome. The secondary outcomes were heart rate variability (HRV) and adverse events.Results. The VAS demonstrated a significant decrease (Pvalue <0.001) for the experimental group after 15 minutes of acupuncture. The variation in HRV showed no significant difference in either group. No adverse event was reported.Conclusion. Acupuncture might provide immediate effect in reducing the pain of acute LBP safely.

Clinical Efficacy and Safety Analysis on Targeted Nursing Intervention Combined with Drug Therapy of Aspirin and Clopidogrel in the Treatment of Ischemic Stroke

2021 ◽  
Vol 7 (5) ◽  
pp. 3988-3996
Author(s):  
Wanjiao Tang ◽  
Chilei Ma
Keyword(s):  
Ischemic Stroke ◽  
Drug Therapy ◽  
Platelet Aggregation ◽  
Clinical Efficacy ◽  
Nursing Intervention ◽  
Control Group ◽  
Efficacy And Safety ◽  
Hs Crp ◽  
Experimental Group ◽  
Better Than

Objective. The purpose of the study was to investigate the clinical efficacy and safety of targeted nursing intervention combined with drug therapy of aspirin and clopidogrel in the treatment of ischemic stroke. Methods. A total of 118 ischemic stroke patients admitted to our hospital from January 2018 to January 2020 were selected and divided into control group (n=59) and experimental group (n=59) according to the order of admission, and their clinical data were retrospectively analyzed. Among them, the control group patients were treated with aspirin, while the patients in the experimental group received the drug therapy of aspirin combined with clopidogrel. After that, the indexes related to the clinical efficacy and safety of treatment were compared between the two groups. Results. The total effective rate of treatment in the experimental group was significantly higher than that in the control group; the NIHSS and ADL scores in both groups after treatment were significantly better than those before treatment, and after treatment, the NIHSS and ADL scores in the experimental group were significantly better than those in the control group; the serum hs-CRP levels and platelet aggregation rate of the patients after treatment were significantly lower than those before treatment, and the serum hs-CRP levels and platelet aggregation rate of the patients in the experimental group were lower than those in the control group, and after treatment, the mean hs-CRP levels of the patients in the experimental group were within the normal range, with statistically significant differences; during treatment, there were 2 cases of epistaxis in the control group, and 1 case of epistaxis as well as 2 cases of gingival bleeding in the experimental group, and there were no adverse reactions occurring in patients’ skin and mucosa, digestive tract, brain, etc. Conclusion. Over a short period of time, targeted nursing intervention combined with drug therapy of aspirin and clopidogrel, with obvious clinical efficacy and high safety, can effectively improve serum hs-CRP levels, inhibit platelet aggregation as well as improve prognosis in patients.

Sign in / Sign up

Export Citation Format

Share Document